Editorial: Insights in cellular endocrinology: 2022

Front Endocrinol (Lausanne). 2023 Nov 30:14:1334003. doi: 10.3389/fendo.2023.1334003. eCollection 2023.
No abstract available

Keywords: asprosin; diabetes; gpcr; guanylyl cyclase C; leptin; metabolic diseases; nanobodies; obesity.

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Endocrinology*
  • Peptide Hormones*

Substances

  • Peptide Hormones

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The work of RJ was supported by the Agence Nationale de la Recherche (ANR-19-CE16-0025-01 « mitoGPCR », ANR-21-CE18-0023 «alloGLP1R»; ANR: Appel RA-Covid-19 project MELATOVID (ANR-20-COV4-0001), the Fondation pour la Recherche Médicale (Equipe FRM DEQ20130326503), the European Union’s Horizon Europe Research and Innovation Program under grant agreement 101080465, the Institut National de la Santé et de la Recherche Médicale (INSERM) and the Centre National de la Recherche Scientifique (CNRS). OG is Staff Personnel (I3SNS Stable Researcher) of Xunta de Galicia (Servizo Galego de Saude (SERGAS)) through a research-staff contract (ISCIII/SERGAS). OG is member of RICORS Programme, [RD21/0002/0025]. The work of OG [PI20/00902] is funded by ISCIII, European Union, European Commission and FEDER. OG is beneficiary of a Grant from Sociedad Española de Columna Vertebral (GEER). BECAS INVESTIGACION GEER 2020 and 2023. OG is member of the COST Action CA21110-BUILDING AN OPEN EUROPEAN NETWORK ON OSTEOARTHRITIS RESEARCH (NetwOArk) funded by European Union and European Commission under the European Cooperation in Science and technology Programme (COST). OG is the beneficiary of a grant funded by Xunta de Galicia, Consellería de Educacion, Universidade e Formacion Profesional and Consellerıa de Economıa, Emprego e Industria, Axencia Galega de Inovación (GAIN) [GPC IN607B2022/02].